蛋白酶体抑制剂硼替佐米联合顺铂对宫颈癌细胞增殖的影响
Effects of proteasome inhibitor bortezomib combined with cisplatin on proliferation of human cervical cancer cells

DOI: 10.6040/j.issn.1671-7554.0.2017.138

Keywords: 蛋白酶体抑制剂,顺铂,Rb蛋白,宫颈癌,Hela细胞,硼替佐米,p53蛋白,
Bortezomib,p53 protein,Hela cell,Proteasome inhibitor,Cisplatin,Rb protein,Ceivical cancer

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Nachajova M, Brany D, Dvorska D. Telomerase and the process of cervical carcinogenesis[J]. Tumor Biology, 2015, 36(10): 7335-7338.
[2]	Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review[J]. Expert Opin Drug Saf, 2015, 14(5): 697-712.
[3]	Tomaic V, Pim D, Thomas M, et al. Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD[J]. J Virol, 2011, 85(7): 3120-3127.
[4]	Todorovic B, Hung K, Massimi P, et al. Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor[J]. J Virol, 2012, 86(24): 13313-13323.
[5]	Au Yeung CL, Tsang TY, Yau PL, et al. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway[J]. Oncogene, 2011, 30(21): 2401-2410.
[6]	Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination[J]. Am J Public Health, 2013, 103(8): 1428-1435.
[7]	Heley S. Human papillomavirus: beware the infection you cant see[J]. Aust Fam Physician, 2003, 32(5): 311-315.
[8]	Kennedy EM, Kornepati AV, Goldstein M, et al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease[J]. J Virol, 2014, 88(20):11965-11972.
[9]	Shiho O, Ning M, Raynoo T. DNA Damage in inflammation-related carcinogenesis and cancer stem cells[J]. Oxid Med Cell Longev, 2013, 2013: 387014. doi: 10.1155/2013/387014.
[10]	孙晓莉, 高美华, 王在秋, 等. HPV-DNA与TCT联合检测在宫颈癌诊断中的应用[J]. 现代生物医学进展, 2012, 12(9):1745-1747. SUN Xiaoli, GAO Meihua, WANG Zaiqiu, et al. Application of HPV-DNA detecting with TCT test in cervical carcinoma diagnosis[J]. Progress in Modern Biomedicine, 2012, 12(9): 1745-1747.
[11]	Toft L, Storgaard M, Muller M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial[J]. J Infect Dis, 2014, 209(8): 1165-1173.
[12]	Ljubojevic S. The human papillomavirus vaccines[J]. Acta Dermatovenerol Croat, 2006, 14(3): 208.
[13]	Barac YD, Emrich F, Krutzwakd-Josefson E, et al. The ubiquitin-proteasome system: a potential therapeutic target for heart failure[J]. J Heart Lung Transplant, 2017, 36(7): 708-714.
[14]	Nevins JR. The Rb/E2F pathway and cancer[J]. Hum Mol Genet, 2001, 10(7): 699-703.
[15]	Liu H, Li X, Ning G, et al. The Machado-Joseph disease deubiquitinase ataxin-3 regulates the stability and apoptotic function of p53[J]. PLoS Biol, 2016, 14(11): e2000733. doi: 10.1371/journal.pbio.2000733.
[16]	Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention[J]. Gynecol Oncol, 2008, 110(Suppl 1): 18-25.
[17]	钟明星,邱帅. 硼替佐米联合地塞米松用于多发性骨髓瘤治疗的临床观察[J]. 中国医院药学杂志, 2016, 36: 292.
[18]	任金海,郭晓楠. 多发性骨髓瘤诊断与治疗的研究进展[J]. 临床荟萃, 2017, 32(2): 177-180. REN Jinhai, GUO Xiaonan. Research progress of diagnosis and treatment of multiple myeloma[J]. Clinical Fous, 2017, 32(2): 177-180.
[19]	Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer[J]. N Engl J Med, 2014, 370(8): 734-743.
[20]	刘亚飞,张奇舒,袁首道,等. HPV永生化细胞系与SiHa细胞系蛋白质表达差异的质谱分析[J]. 山东大学学报(医学版), 2015, 53(3): 22-26. LIU Yafei, ZHANG Qishu, YUAN Shoudao, et al. Mass spectrometry analysis of differentially expressed proteins between HPV immortalized cell line and SiHa cell line[J]. Journal of Shandong University(Health Sciences), 2015, 53(3): 22-26.
[21]	Chen R, Zhang H, Liu P, et al. Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma[J]. J Cancer, 2017, 8(5): 839-851.
[22]	Virag P, Perde-Schrepler M, Fischer-Fodor E, et al. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines[J]. Anticancer Drugs, 2012, 23(10): 1032-1038.
[23]	Bulbul P, Andrei LG. Proteasome inhibitors induce p53-independent apoptosis in human cancer cells[J]. Am J Pathol, 2011, 178(1): 355-360.
[24]	Adams J. The development of proteasome inhibitors as anticancer drugs[J]. Cancer Cell, 2004, 5(5): 417-421.
[25]	Liu X, Roberts J, Dakic A, et al. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function[J]. Virology, 2008, 375(2): 611-623.
[26]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
[27]	de Villiers EM. Cross-roads in the classification of papillomaviruses[J]. Virology, 2013, 445(1-2): 2-10.
[28]	蒲业迪, 李丽珍,马道新,等. 硼替佐米耐药多发性骨髓瘤细胞株KM3/BTZ的建立[J]. 山东大学学报(医学版), 2013, 51(2): 33-36. PU Yedi, LI Lizhen, MA Daoxin, et al. Establishment of a bortezomib-resistant cell line KM3 /BTZ of human multiple myeloma[J].Journal of Shandong University(Health Sciences), 2013, 51(2): 33-36.

Full-Text